Cathie Wood's ARK sells Palantir stock, buys Beam and Bullish

On November 3rd, 2025, Cathie Wood's ARK ETFs executed significant portfolio reallocations, notably purchasing 238,346 shares of Bullish (BLSH) for over $12 million and 336,257 shares of Beam Therapeutics (BEAM) for $8.4 million, underscoring a continued investment in crypto-related assets and a growing interest in the biotech sector. Simultaneously, ARK divested 38,338 shares of Palantir Technologies (PLTR) for $7.6 million, alongside reducing positions in Roku (ROKU), Guardant Health (GH), and Adaptive Biotechnologies (ADPT), reflecting a strategic shift away from these holdings.

Analysis

Cathie Wood's ARK ETFs executed significant portfolio reallocations on November 3rd, 2025, demonstrating a clear strategic shift towards specific growth sectors. The most substantial purchase was 238,346 shares of Bullish (BLSH) across ARKK, ARKW, and ARKF, valued at over $12 million, continuing a recent trend in crypto-related assets. Concurrently, ARK acquired 336,257 shares of Beam Therapeutics (BEAM) for $8.4 million via ARKK and ARKG, signaling a growing conviction in the biotech sector.

These acquisitions were funded by notable divestments from existing holdings. ARK reduced its Palantir Technologies (PLTR) position by selling 38,338 shares for $7.6 million through ARKK, extending a recent trend of trimming this holding. Further reductions included 21,793 shares of Roku (ROKU) for $2.3 million, 13,426 shares of Guardant Health (GH) for $1.2 million, and 46,710 shares of Adaptive Biotechnologies (ADPT) for $0.8 million.

The collective trading activity underscores ARK's strategic reallocation of capital towards high-conviction growth areas like gene editing (BEAM) and digital assets (BLSH). This aggressive portfolio rebalancing indicates a move away from previous holdings, suggesting a revised outlook on their long-term growth potential or a desire to consolidate capital into fewer, higher-conviction bets. The market's overall mildly positive sentiment and optimistic tone, despite these specific divestments, suggest that ARK's movements are being watched as a bellwether for specific tech and biotech sub-sectors.

Key Decisions for Investors

• Investors should evaluate ARK's increased conviction in Beam Therapeutics (BEAM) and Bullish (BLSH) as a signal for potential growth in gene editing and digital asset sectors, respectively.
• Consider reassessing positions in Palantir (PLTR), Roku (ROKU), Guardant Health (GH), and Adaptive Biotechnologies (ADPT), given ARK's continued divestment, which may indicate a shifting long-term outlook from a prominent growth investor.
• Monitor ARK's future trading patterns for further insights into their strategic reallocations, particularly regarding their focus on specific biotech and crypto-related assets, as these moves often reflect broader thematic shifts among growth-oriented funds.